You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Philadelphia chromosome positive

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Chicago, Illinois
  • +5 more
Dec 27, 2021

Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in

Not yet recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +3 more
  • Olverembatinib, APG-2575, Dexamethasone
  • Hefei, Anhui, China
  • +3 more
Aug 8, 2022

Ph+ ALL Trial in China (Olverembatinib, Imatinib)

Recruiting
  • Ph+ ALL
  • Chongqing, Chongqing, China
  • +8 more
Sep 22, 2023

Acute Leukemia Trial in Tianjin (Flumatinib, Imatinib)

Recruiting
  • Acute Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Sep 27, 2021

Iclusig PMS in CML or Ph+ALL Patients

Recruiting
  • Chronic Myeloid Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Busan, Korea, Republic of
    Kosin University Gaspel Hospital
Sep 16, 2021

B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Nov 8, 2023

Chronic Myeloid Leukemia, Chronic Phase Trial in Beijing (Radotinib, Imatinib)

Active, not recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Beijing, China
    Peking University People's Hospital(北京大学人民医院)
Jan 3, 2022

Myeloid Leukemia, Philadelphia Positive Trial in Worldwide (Asciminib Pediatric formulation group, Asciminib Adult formulation

Recruiting
  • Myeloid Leukemia, Philadelphia Positive
  • Asciminib Pediatric formulation group
  • Asciminib Adult formulation group
  • Boston, Massachusetts
  • +24 more
Jan 17, 2023

Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Completed
  • Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
  • Cairo, Egypt
    National Cancer Institute (NCI)
Feb 22, 2021

Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL Trial in Italy (Ponatinib

Recruiting
  • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
  • +2 more
  • Ponatinib + Blinatumomab
  • Chemotherapy + Imatinib
  • Ascoli Piceno, Italy
  • +14 more
Jan 3, 2022

Chronic Myelogenous Leukemia - Chronic Phase Trial in United States (Nilotinib)

Terminated
Has Results
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Los Angeles, California
  • +10 more
Jul 26, 2021

ALL Trial in Spain (Prednisone, Vincristine, Daunorubicin)

Active, not recruiting
  • ALL
  • Badalona, Spain
  • +9 more
Feb 17, 2022

CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib

Terminated
Has Results
  • CML
  • +2 more
  • Las Vegas, Nevada
  • +2 more
Apr 28, 2021

Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL),

Recruiting
  • Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
  • +2 more
  • Phoenix, Arizona
  • +69 more
Aug 23, 2022

Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL Trial in Spain (blinatumomab)

Terminated
  • Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
  • Badalona, Barcelona, Spain
  • +11 more
Jul 26, 2022

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Worldwide (STI571

Completed
Has Results
  • Philadelphia Positive Chronic Myeloid Leukemia
  • +2 more
  • STI571 400 mg
  • STI571 600 mg
  • Boston, Massachusetts
  • +11 more
Jul 1, 2021

Previously Treated PH + CML Trial in Worldwide (Bosutinib)

Terminated
Has Results
  • Previously Treated PH + CML
  • Los Angeles, California
  • +47 more
Dec 2, 2021

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +5 more
  • Blinatumomab
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2022

Acute Lymphoblastic Leukemia, Adult Trial (Ponatinib, Blinatumomab, Imatinib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • (no location specified)
Dec 28, 2020

Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in France (Ponatinib, Imatinib)

Recruiting
  • Philadelphia Chromosome Positive CML
  • BCR-ABL Positive Chronic Myelogenous Leukemia
  • Amiens, France
  • +27 more
Dec 9, 2021

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,

Terminated
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +10 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Nov 17, 2021

Chronic Myelogenous Leukemia Trial in Turkey (Nilotinib)

Completed
Has Results
  • Chronic Myelogenous Leukemia
  • Eskisehir, Meselik, Turkey
  • +12 more
Aug 18, 2020

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)

Completed
  • Chronic Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
  • Tokyo, Japan
    Novartis Investigative Site
Dec 6, 2020